Abstract
Melanoma rarely occurs in pediatric patients, so health care professionals must make special considerations to ensure an accurate diagnosis and to plan appropriate treatment for this age group. Because there are limited data on melanoma in pediatric patients, the guidelines presented here are based on reports of melanoma in adults. However, issues specific to the diagnosis and treatment of pediatric patients with melanoma are addressed.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Readings
Bacchi CE, Bonetti F, Pea M, et al. HMB-45: a review. Appl Immunohistochem 1996;4:73–85.
Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635–3648.
Balch CM, Soong S-J, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622–3634.
Binder SW, Ansong C, Paul E, et al. The histology and differential diagnosis of Spitz nevus. Semin Diagn Pathol 1998;10:36–46.
Ceballos PI, Ruiz-Maldonado R, Mihm MCJ. Melanoma in children. N Engl J Med 1995;332:656–662.
Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998;16:2253–2260.
Gershenwald JE, Thompson W, Mansfield PF, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999;17:976–983.
Handfield-Jones SE, Smith NP. Malignant melanoma in childhood. Br J Dermatol 1996;34:607–616.
Kirkwood JM, Ibrahim JG, Sondak VK, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup Trial E1690/S9111/C91190. J Clin Oncol 2000;18:2444–2458.
Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup Trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–2380.
Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17.
Lohmann CM, Coit DG, Brady MS, et al. Sentinel lymph node biopsy in patients with diagnostically controversial Spitzoid melanocytic tumors. Am J Surg Pathol 2002;26:47–55.
NIH Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992;268:1314–1319.
Prieto VG, Clark SH. Processing of sentinel lymph nodes for detection of metastatic melanoma. Ann Diagn Pathol 2002;6:257–264.
Prieto VG, McNutt NS, Lugo J, et al. The intermediate filament peripherin is expressed in cutaneous melanocytic lesions. J Cutan Pathol 1997;24:145–150.
Reed JA, Finnerty B, Albino AP. Divergent cellular differentiation pathways during the invasive stage of cutaneous malignant melanoma progression. Am J Pathol 1999;155:549–555.
Rudolph P, Schubert C, Schubert B, et al. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Dermatol 1997;37:169–178.
Ruiz-Maldonado R, Orozco-Covarrubias M. Malignant melanoma in children. A review. Arch Dermatol 1997;133:363–371.
Scalzo DA, Hida CA, Toth G, et al. Childhood melanoma: a clinicopathological study of 22 cases. Melanoma Res 1997;7:63–68.
Su LD, Fullen DR, Sondak VK, et al. Sentinel lymph node biopsy for patients with problematic Spitzoid melanocytic lesions. Cancer 2003;97:499–507.
Sumner WEI, Ross MI, Mansfield PF, et al. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer 2002;95:354–360.
Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA 1997;277:1439–1444.
Walsh N, Crotty K, Palmer A, et al. Spitz nevus versus spitzoid malignant melanoma: an evaluation of the current distinguishing histopathologic criteria. Hum Pathol 1998;29:1105–1112.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Herzog, C.E., Diwan, H., Ross, M.I., Prieto, V.G. (2005). Melanoma. In: Chan, K.W., Raney, R.B. (eds) Pediatric Oncology. M.D. Anderson Cancer Care Series, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-24472-3_13
Download citation
DOI: https://doi.org/10.1007/978-0-387-24472-3_13
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-24470-9
Online ISBN: 978-0-387-24472-3
eBook Packages: MedicineMedicine (R0)